Sequana Medical announces Extraordinary General Meeting of Shareholders on 10 February 2023
11January 2023, 07:00 am CEST
Ghent, Belgium – 11 January 2023– Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "SequanaMedical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today invites the holders of securities issued by the Company to attend the Extraordinary General Meeting of Shareholders on Friday, 10 February 2023.
The items on the agendas of the meeting include (amongst other things) the proposed approval of the appointment of Douglas Kohrs and Alexandra Taylor Clyde as independent non-executive directors, the approval of certain amendments to the Company's remuneration policy, and the issuance of "Kreos Subscription Rights" (in the form of subscription rights).
The Extraordinary General Meeting of Shareholders will take place at the Company's registered offices in Ghent and will start at 09:00 am CEST. The full convening notice with the agenda and proposed resolutions can be accessed on the Sequana Medical website: www.sequanamedical.com/investors/shareholder-information.
In light of the COVID-19 pandemic, it is possible that certain measures imposed by the Belgian government to deal with this pandemic may (still) be in effect on the date of the Extraordinary General Meeting of Shareholders. Therefore, the Board of Directors recommends that the holders of securities issued by the Company that wish to participate to the meeting make use, as much as practically possible, of the right to vote through voting by mail or by means of a written proxy to the Chair of the Board of Directors.
The Company will grant access to the meeting to security holders, proxy holders and other persons only to the extent permitted in light of the measures taken or to be taken by the authorities as applicable on the date of the meeting, and always taking into account the recommendations of the authorities, and safety and health considerations.
The Company recommends the holders of its securities to use e-mail for all communications with the Company regarding the Extraordinary General Meeting of Shareholders. The Company's e-mail address for such communications is: IR@sequanamedical.com.
For more information, please contact:
Director Investor Relations
T: +32 (0)498 05 35 79
Optimum Strategic Communications
Mary Clark, Nick Bastin, Vici Rabbetts
T: +44 (0)7931 500 066
About Sequana Medical
Sequana Medical NV is a pioneer in treating fluid overload, a serious and frequent clinical complication in patients with liver disease, heart failure and cancer. These patients can have up to 15 liters of extra fluid in their bodies, causing major medical issues including increased mortality, repeated hospitalizations, severe pain, difficult breathing and restricted mobility that severely impacts daily life. Although diuretics are standard of care, the problem is that in many patients they are no longer effective and / or tolerable. There are limited effective treatment options for these patients resulting in poor clinical outcomes, high costs and major impact on their quality of life. Sequana Medical is seeking to provide innovative treatment options for this large and growing “diuretic-resistant” patient population.
alfapump® and DSR® are Sequana Medical's proprietary platforms that work with the body to treat diuretic-resistant fluid overload, delivering major clinical and quality of life benefits for patients and reducing costs for healthcare systems. The Company has reported positive primary endpoint data from the North American pivotal POSEIDON study of the alfapump in recurrent or refractory ascites due to liver cirrhosis, enabling the filing of a Pre-Market Approval (PMA) application with the FDA, planned for H2 2023. Having delivered clinical proof-of-concept for DSR as a disease-modifying drug program for the treatment of heart failure, the Company is planning to commence MOJAVE, a US multi-centered randomized controlled Phase 1/2a clinical study of DSR 2.0, in H1 2023.
Sequana Medical is listed on Euronext Brussels (Ticker: SEQUA.BR) and headquartered in Ghent, Belgium. For further information, please visit www.sequanamedical.com.
Important Regulatory Disclaimers
The alfapump® system is currently not approved in the United States or Canada. In the United States andCanada, the alfapump system is currently under clinical investigation (POSEIDON Study) and is being studied inadult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding thePOSEIDON clinical study see www.poseidonstudy.com. DSR® therapy is still in development and it should benoted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinicalinvestigations which have yet to be completed. DSR therapy is currently not approved for clinical research in theUnited States or Canada. There is no link between DSR therapy and ongoing investigations with the alfapumpsystem in Europe, the United States or Canada.
Note: alfapump® is a registered trademark. DSR® is a registered trademark in the Benelux, China, the EU, UnitedKingdom, and Hong Kong.
This press release may contain predictions, estimates or other information that might be consideredforward-looking statements. Such forward-looking statements are not guarantees of future performance.Theseforward-looking statements represent the current judgment of Sequana Medical on what the futureholds,and are subject to risks and uncertainties that could cause actual results to differ materially. Sequana Medicalexpressly disclaims any obligation or undertaking to release any updates or revisions to any forward-lookingstatements in this press release, except if specifically required to do so by law or regulation. You should notplace undue reliance on forward-looking statements, which reflect the opinions of Sequana Medical only as ofthe date of this press release.
AttachmentsTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Unibail-Rodamco-Westfield SE: Holding conditions for the Combined General Meeting of Unibail-Rodamco-Westfield SE on May 11, 2023, availability of its explanatory documentation and the 2022 Universal Registration Document27.3.2023 18:46:42 CEST | Press release
Paris, Amsterdam, March 27, 2023 Press release Holding conditions for the Combined General Meeting of Unibail-Rodamco-Westfield SE on May 11, 2023, availability of its explanatory documentation and the 2022 Universal Registration Document The Combined General Meeting of shareholders of Unibail-Rodamco-Westfield SE will be held at Palais des Congrès de Paris (2, place de la Porte Maillot, Espace Ternes – 75017 Paris, France) on Thursday May 11, 2023, at 10:30 am (Paris time). The formal notice to shareholders (Avis de réunion à l’Assemblée Générale valant avis de convocation) was published today, in the BALO (Bulletin des Annonces Légales Obligatoires) and set out the Combined General Meeting agenda, the proposed resolutions, as well as the terms and conditions for voting at this General Meeting. The 2022 Universal Registration Documentof Unibail-Rodamco-Westfield SE was filed today with the French Financial Markets Authority (Autorité des Marchés Financiers). The 2022 Universal Registr
RCI Banque: Issuance of Eur 750 Million Fixed Rate Notes Maturing in April 202727.3.2023 18:30:00 CEST | Press release
March 27th, 2023 RCI BANQUE: ISSUANCE OF EUR 750 MILLION FIXED RATE NOTES MATURING IN APRIL 2027 RCI Banque announces the issuance of a € 750 m 4-year bond bearing a 4.50% coupon. The deal attracted more than € 1.1 billion final order book coming from 90 subscribers. In a context of volatile market conditions, RCI Banque would like to thank the investors that participated to the trade for their renewed and their willingness to support its business. About Mobilize Financial Services: As a partner caring for all its customers, Mobilize Financial Services builds innovative financial services to create sustainable mobility for all. A subsidiary of the Renault Group whose activity started almost 100 years ago, Mobilize Financial Services is the commercial brand of RCI Banque SA, a French Bank specializing in automotive financing and services for Alliance customers and dealers. With operations in 35 countries and nearly 4,000 employees, the group financed over 1.2 million contracts (new and
Decisions Adopted by eQ Plc's Annual General Meeting27.3.2023 18:30:00 CEST | Press release
eQ Plc Stock Exchange Release 27 March 2023, at 7.30 p.m. eQ Plc’s Annual General Meeting, held on Wednesday 27 March 2023 in Helsinki (“AGM”), decided upon the following: Confirmation of the financial statements eQ Plc’s AGM confirmed the financial statement of the company, which included the group financial statements, the report by the Board of Directors and the auditor’s report for the financial year 2022. Decision in respect of the result shown on the balance sheet and distribution of the assets from the invested unrestricted equity fund The AGM confirmed the proposal by the Board of Directors that a dividend of 0.91 euros per share and a return of capital of 0.09 euros per share be paid from the invested unrestricted equity fund. The dividend and return of capital shall be paid to shareholders who on the record date for the payment, 29 March 2023, are recorded in the shareholders register held by Euroclear Finland Ltd. The dividend and return of capital shall be paid on 5 April 2
Wood Mackenzie appoints new Chief Financial Officer27.3.2023 18:22:05 CEST | Press release
Simon Crowe, formerly of ERM, brings sustainability and energy industry experience LONDON and HOUSTON and SINGAPORE, March 27, 2023 (GLOBE NEWSWIRE) -- Wood Mackenzie, a portfolio company of Veritas Capital, has appointed Simon Crowe to its global executive leadership team as Chief Financial Officer (CFO), effective 27th March. Simon brings a wealth of experience in private and public companies in the US, Europe and Asia. He joins Wood Mackenzie after nearly five years as CFO of ERM, the world’s largest Sustainability and Environmental Consultancy where he played a key role in their rapid growth, diversification, and successful investment from KKR. Commenting on Simon’s appointment, Mark Brinin, CEO of Wood Mackenzie said: “Simon is a commercially minded CFO, with a breadth of international experience, having worked with private equity backed ERM and companies listed on New York, London and European stock exchanges. He has strong financial management and strategic leadership skills. Si
BBS-Bioactive Bone Substitutes – Inside information: The final report of the second audit received from the Notified Body, CE marking process may continue and CE marking approval continues to be expected during 202327.3.2023 18:20:00 CEST | Press release
BBS-Bioactive Bone Substitutes, Company announcement, Insider information, 27 March 2023 at 7:20 p.m. EEST BBS-Bioactive Bone Substitutes – Inside information: The final report of the second audit received from the Notified Body, CE marking process may continue and CE marking approval continues to be expected during 2023 The Notified Body has completed its second audit. The audit was carried out during 10-13 March 2023, the audit report was received on 20 March 2023, and today on 27 March 2023 the last meeting related to the audit was held with the authorities. The second audit was related to the approval process of BBS-Bone Substitutes Plc’s quality system, which is part of the CE marking process for the company's first product (ARTEBONE® Paste -bone filler). During the second audit, the Notified Body inspected more closely detailed product documentation and the production processes. According to the final audit report, certain additional measures are required from the company, and th